Asthma is significantly more common among patients with multiple sclerosis (MS) than in the general population, a new study shows. The increased prevalence was especially evident in younger and ... Read more
As the protective molecular caps of our genetic information — called telomeres — become shorter in certain immune cells, the extent of multiple sclerosis (MS) disability progression increases, regardless of ... Read more
Patients with relapsing-remitting multiple sclerosis (RRMS), particularly those with multiple conditions who are more severely disabled, are more likely to be using several medications at the same time, a study ... Read more
Risk factors often associated with multiple sclerosis (MS), such as genetic background, obesity and smoking, contribute independently to the disease’s variability and may be an early influence on progression, ... Read more
A recent study found that elder individuals with multiple sclerosis (MS) experience significantly less severe depressive symptoms and better quality of life than their younger counterparts. The research, “Subjective ... Read more
The levels of three small, regulatory RNA molecules — long non-coding RNAs — are deregulated in blood samples of patients with relapsing-remitting multiple sclerosis (RRMS), a study reports. The ... Read more
New retrospective analysis of the Phase 3 CLARITY study (NCT00213135) shows that treatment with Mavenclad (cladribine tablets) improved annualized relapse rate and magnetic resonance imaging (MRI) outcomes in patients with relapsing-remitting ... Read more
A lot of people with multiple sclerosis take disease-modifying therapies to reduce the inflammation associated with the disease — but in many patients, the treatments’ effectiveness wanes at a certain points.
When ... Read more
The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) has awarded five young investigators for their research work on multiple sclerosis (MS). The awards were presented at the ACTRIMS ... Read more
Older patients with secondary progressive multiple sclerosis (SPMS) have reduced risk of experiencing disease relapse, according to a study presented at the 7th Joint ECTRIMS-ACTRIMS Meeting, being held Oct. 25-28, ... Read more
Patients with primary progressive multiple sclerosis have more severe cognitive impairment than those with relapsing-remitting multiple sclerosis, according to a German study that analyzed published data on the topic.
PPMS ... Read more
A study analyzing results from three Phase 3 clinical trials shows that Gilenya (fingolimod) effectively prevents relapses in different types of relapsing multiple sclerosis (MS) patients, with the therapy ... Read more
Most research in multiple sclerosis (MS) has focused on the impact of the disease on the lower extremities. To balance this, researchers at Mount Sinai Rehabilitation Hospital in Connecticut ... Read more